LAVA Therapeutics N.V.
LVTX
$1.28
$0.043.23%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1,313.60% | -- | -- | 471.24% | -86.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,313.60% | -- | -- | 471.24% | -86.63% |
| Cost of Revenue | -24.95% | -- | -- | -- | -- |
| Gross Profit | 39.56% | -- | -- | 2,278.23% | -1,325.76% |
| SG&A Expenses | 21.84% | -2.55% | -18.18% | -24.55% | 2.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.90% | 4.68% | -49.90% | -39.42% | -57.96% |
| Operating Income | 42.75% | -5.20% | 30.89% | 85.58% | 51.36% |
| Income Before Tax | 43.52% | -38.86% | 34.85% | 96.51% | 57.19% |
| Income Tax Expenses | 874.36% | 92.00% | -12.37% | -2.82% | -41.79% |
| Earnings from Continuing Operations | 37.92% | -39.16% | 34.68% | 96.03% | 57.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.92% | -39.16% | 34.68% | 96.03% | 57.12% |
| EBIT | 42.75% | -5.20% | 30.89% | 85.58% | 51.36% |
| EBITDA | 42.47% | -5.62% | 31.00% | 86.52% | 52.13% |
| EPS Basic | 38.13% | -36.27% | 35.98% | 96.12% | 57.89% |
| Normalized Basic EPS | 104.85% | -35.95% | 36.15% | 96.57% | 57.96% |
| EPS Diluted | 38.13% | -36.27% | 35.98% | 96.12% | 57.89% |
| Normalized Diluted EPS | 104.85% | -35.95% | 36.15% | 96.57% | 57.96% |
| Average Basic Shares Outstanding | 0.36% | 2.12% | 2.03% | 1.92% | 1.83% |
| Average Diluted Shares Outstanding | 0.36% | 2.12% | 2.03% | 1.92% | 1.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |